LSD阻害因子とPD1結合アンタゴニストの組み合わせによるT細胞機能の増強およびT細胞機能障害性障害の治療
本発明は、T細胞機能を増強する、またはT細胞機能障害性障害を治療するための組成物であって、リジン特異的脱メチル化酵素(LSD)阻害因子(MAO阻害剤またはフェネルジンであり得る)とプログラム細胞死タンパク質1(PD−1)結合アンタゴニスト(抗体、好ましくはニボルマブ、ペンブロリズマブ、ランブロリズマブまたはピジリズマブであり得る)とを含む、これらからなるまたはこれらから本質的になる組成物に関する。.
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Europäisches Patentamt - (2021) vom: 15. Feb. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Japanisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-02-15, Last update posted on www.tib.eu: 2024-04-02, Last updated: 2024-04-09 |
---|
Patentnummer: |
JP2021504399 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA002838508 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA002838508 | ||
003 | DE-627 | ||
005 | 20240409143650.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240329s2021 xx |||||o 00| ||jpn c | ||
035 | |a (DE-627)EPA002838508 | ||
035 | |a (EPA)JP2021504399 | ||
035 | |a (EPA)66663674 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a jpn | ||
245 | 1 | 0 | |a LSD阻害因子とPD1結合アンタゴニストの組み合わせによるT細胞機能の増強およびT細胞機能障害性障害の治療 |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2021-02-15, Last update posted on www.tib.eu: 2024-04-02, Last updated: 2024-04-09 | ||
520 | |a 本発明は、T細胞機能を増強する、またはT細胞機能障害性障害を治療するための組成物であって、リジン特異的脱メチル化酵素(LSD)阻害因子(MAO阻害剤またはフェネルジンであり得る)とプログラム細胞死タンパク質1(PD−1)結合アンタゴニスト(抗体、好ましくはニボルマブ、ペンブロリズマブ、ランブロリズマブまたはピジリズマブであり得る)とを含む、これらからなるまたはこれらから本質的になる組成物に関する。 | ||
650 | 4 | |a bio | |
650 | 4 | |a tec | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
650 | 4 | |a che | |
650 | 4 | |a C12Q: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (immunoassay g01n0033530000); compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processes | |
650 | 4 | |a 615 | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 15. Feb. |
773 | 1 | 8 | |g year:2021 |g day:15 |g month:02 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/66663674/publication/JP2021504399A1?q=JP2021504399 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2021 |b 15 |c 02 |